The FDA approved Neurontin in 1994 for treatment of partial seizures usually associated with epilepsy. It was later approved for pain management associated with postherpetic neuralgia as a result of shingles.
Shortly after Neurontin appeared on the market, the manufacturer, Pfizer, began intensive marketing of the drug for off-label purposes not approved by the FDA, including bipolar disorder, attention deficit disorder, migraines and drug and alcohol withdrawal.
Pfizer also marketed the drug for use as a first-line monotherapy treatment for epilepsy, which the FDA had previously rejected. Pfizer continued to implement marketing techniques that illegally promoted Neurontin, influencing off-label uses based on unproven claims. These actions may have caused both patients and doctors to be unable to weigh both the benefits and risks of using the drug.
To learn more about legal claims relating to Neurontin, consult an attorney who practices in the area of drugs and medical devices.
For the second time in the last 15 months, Donald Trump faces trial in the United States Senate as part of the impeachme... Read More
As a general rule, a misdemeanor is a criminal offense that carries a penalty of up to one year in detention. In most in... Read More
What Would Be Required to Change How Presidents Are Elected? The unique method by which the United States elects a pres... Read More
How It Works